Abstract:

Diabetic retinopathy (DR) is a retinal vascular disease caused by hyperglycemia. Neuroinflammation plays an important role in the pathogenesis of DR. In the hyperglycemic environment, some retina glial cells and neurons can release various inflammatory mediators, causing the up-regulation of inflammatory mediators, thus causing retina neuroinflammation in diabetic patients. Electrophysiological changes in the neuroretina happen prior to fundus microvascular lesion, suggesting neuroinflammation may become a new drug target for the prevention and treatment of DR. Drugs that inhibit neuroinflammation include minocycline, hesperetin, cannabidiol, aspirin and salicylate, aldose reductase inhibitors and so on. (Int Rev Ophthalmol, 2018, 42:  153-158)